Evidence map›Paper›PMID 40855114›Full record

ArticleExperimental & molecular medicine2025

The role of Ephexin1 in translation and mTOR-targeted cancer therapy.

Jeeho Kim, In-Youb Chang, Jung-Hee Lee, Jeongsik Yong, Young Jin Jeon, Ho Jin You

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeeho KimLaboratory of Genomic Instability and Cancer therapeutics, Chosun University School of Medicine, Gwangju, South Korea.ORCID http://orcid.org/0000-0001-6869-3606
In-Youb ChangDepartment of Anatomy, Chosun University School of Medicine, Gwangju, South Korea.
Jung-Hee LeeLaboratory of Genomic Instability and Cancer therapeutics, Chosun University School of Medicine, Gwangju, South Korea.
Jeongsik YongDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Twin Cities, Minneapolis, MN, USA. jyong@umn.edu.ORCID http://orcid.org/0000-0002-2758-0450
Young Jin JeonDepartment of Pharmacology, Chosun University School of Medicine, Gwangju, South Korea. yjjeon@chosun.ac.kr.
Ho Jin YouLaboratory of Genomic Instability and Cancer therapeutics, Chosun University School of Medicine, Gwangju, South Korea. hjyou@chosun.ac.kr.ORCID http://orcid.org/0000-0002-0530-4017

Funding

The Role of Truncated mRNAs in CancerR01GM113952 · NIGMS · UNIVERSITY OF MINNESOTA · PI YONG, JEONGSIK · 2015 to 2023
$3.0M
National Research Foundation of Korea (NRF) NRF-2022R1A5A2030454National Research Foundation of Korea (NRF) RS-2022-NR072262National Research Foundation of Korea (NRF) RS-2024-00350874NIGMS NIH HHS R01 GM113952
6 · The paper itself

Abstract

Ephexin1, also known as neuronal guanine nucleotide exchange factor (NGEF), plays a key role in axon guidance and synaptic homeostasis. However, our recent studies have revealed a critical role for Ephexin1 in the pathogenesis of colon and lung cancers. Here we used multidisciplinary approaches to further explore the underlying mechanisms of Ephexin1 in cancer progression. We discovered that Ephexin1 is essential for promoting polysome formation by coordinating the assembly of translation initiation complexes. Our investigations into gene expression affected by Ephexin1 deficiency showed that Ephexin1 specifically promotes the translation of genes containing 5'-terminal oligopyrimidine (TOP) or 5'-TOP-like motifs, identifying Ephexin1 as a key mediator of mTOR-regulated translation. Importantly, we found that the efficacy of mTOR inhibitors in treating lung cancer was significantly enhanced in a mouse xenograft model when Ephexin1 was deficient. This suggests that Ephexin1 could serve as a synthetic lethality target for mTORC1-targeting therapeutics in cancer treatment. Our findings provide mechanistic insights into the role of Ephexin1 in cancer pathogenesis and highlight its potential as a therapeutic target for improving current cancer treatment strategies.

Indexed as

Guanine Nucleotide Exchange FactorsLung NeoplasmsNeoplasmsProtein BiosynthesisTOR Serine-Threonine KinasesAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMolecular Targeted TherapyMTOR InhibitorsXenograft Model Antitumor AssaysGuanine Nucleotide Exchange FactorsMTOR InhibitorsMTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID40855114
PMCPMC12411628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.